Major Psychedelic Drug Stocks Went Up 7% This Week; Still Down 46% YTD

Today's article highlights the performance of the munKNEE Psychedelic Drug Stocks Index which tracks six (6) psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of ten (10) different psychedelic substances (read 10 Psychedelic Substances And The 36 Companies Researching Them), and have market capitalizations in excess of $50M.

Below are the performances of the 6 constituents this week, in descending order, and in the past 6 weeks (end of October).

  1. Seelos (SEEL): UP 31.7% this week; UP 22.7% in the last 6 weeks
    • Is focused on developing products for the treatment of Central Nervous System disorders and other rare disorders.
  2. Atai (ATAI): UP 14.9% this week; UP 18.3% in the last 6 weeks
    • Is focused on acquiring and developing treatments that lead to paradigm shifts in the mental health space.
  3. Compass Pathways (CMPS): UP 11.5% this week; UP 2.0% in the last 6 weeks
    • Is focused on the development of psilocybin therapy for people with Treatment-Resistant Depression.
  4. GH Research (GHRS): UP 3.1% this week; UP 15.3% in the last 6 weeks
    • Is focused on developing 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
  5. Mind Medicine (MNMD): DOWN 4.7% this week; DOWN 12.3% in the last 6 weeks
    • Is focused on discovering, developing, and deploying therapies to address addiction and mental illness development.
  6. Cybin (CYBN): DOWN 16.3% this week; DOWN 23.4% in the last 6 weeks
    • Is focused on utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for psychiatric disorders.

In total, the Index went UP 7.0% this week, which brought them to an average of 3.0% up in the last 6 weeks.

Six (6) other psychedelic companies are primarily focused on the development, expansion, and operation of ketamine-assisted therapy (KAT) clinics hoping to capitalize on the massive commercial opportunity that exists to treat the two billion people worldwide who suffer from chronic pain, addiction, and substance abuse withdrawal, and depression. All are highly speculative investments and penny stocks with tiny market capitalization and are identified below with a description of each of their commercialization developments:

  1. Awakn Life Sciences Corp.  (NEO: AWAKN|OTCQB: AWKNF)
    • Is concentrating on the treatment of Alcohol Use Disorder (AUM)
      • has 3 KAT clinics, 2 in the U.K. and 1 in Norway and
      • is developing MDMA-assisted therapy for AUM
    •  Is also in the process of developing KAT for Gambling Disorder
    • Go here for the company's latest quarterly (Q2) financial results
  2. Delic Corp. (CSE: DELC|OTCQB: DELCF)
    • Has 13 ketamine-assisted therapy (KAT) clinics in the U.S.
  3. Field Trip Health and Wellness Ltd. (TSXV: FTHW|OTCQB: FTHWF)
    • Is concentrating on therapies for the treatment of resistant depression, post-traumatic stress disorder and disorders affecting the central nervous systems
    • Operates KAT clinics in Canada (3), the U.S. (8) and Europe (1)
  4. Numinus Wellness Inc. (TSX: NUMI|OTCQX: NUMIF)
    • has 3 KAT clinics in Canada;
    • has the ability to undertake treatments using psilocybin and MDMA in Canada as authorized by Health Canada's Special Access Program
    • Has 6 KAT clinics in Utah and 2 in Arizona
  5. Revitalist Lifestyle and Wellness Ltd. (CSE: CALM|OTCQB: RVLWF)
    • Has 10 KAT clinics in 6 states and 9 options on other clinics
  6. Universal Ibogaine Inc. (TSXV: IBO|OTCQB: IBOGF)
    • Is concentrating on the treatment of Opioid Use Disorder using ibogaine which has a “Prescription Drug List” status in Canada (vs. Schedule 1 in the U.S.) facilitating research and development toward medicalization

The above psychedelic-assisted therapy clinic stocks went UP 3.1%, on average, this week and is UP 1.5% since the end of October (6 weeks).

More By This Author:

Conservative Cannabis Stocks Index Up 5.7% In November; Now +4.6% YTD
Ancillary Cannabis Companies Continued To Outperform S&P 500 In November
Major American Cannabis MSO Stocks Up 10% In November; Remain Down 53% YTD

Visit and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.